Steven J. Isakoff, M.D. Ph.D.

Publications

Isakoff SJ.PARP Inhibition Outside of BRCA Mutation Carriers.Clin Adv Hematol Oncol. 2010 Nov;8(11):757-8.
21326153
Isakoff SJ, Baselga J.Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2011 Feb 1;29(4):351-4.
21172881
Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.Rapid targeted mut
20432502
Isakoff SJ.Triple-negative breast cancer: role of specific chemotherapy agents.Cancer J.;16(1):53-61. Review.
20164691
Mina L,Krop I,Zon RT,Isakoff SJ,Schneider CJ,Yu M,Johnson C,Vaughn LG,Wang Y,Hristova-Kazmierski M,Shonukan OO,Sledge GW,Miller KD.A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and
19214387
Naffar-Abu-Amara S, Shay T, Galun M, Cohen N, Isakoff SJ, Kam Z, Geiger B.Identification of novel pro-migratory, cancer-associated genes using quantitative, microscopy-based screening.PLoS ONE. 2008;3(1):e1457.
18213366
Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A,
17021353
Ganesan S, Richardson AL, Wang ZC, Iglehart JD, Miron A, Feunteun J, Silver D, Livingston DM.Abnormalities of the Inactive X Chromosome Are a Common Feature of BRCA1 Mutant and Sporadic Basal-like Breast Cancer.Cold Spring Harb Symp Quant Biol. 2005;70:93
16869742
Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS.The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.Am J Surg. 2006 Jul;192(1):58-62.
16769276
Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu JS, Wong WH.Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data.BMC Bioinformatics. 2006;7:197.
16606446
Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, Li FP, Miron A, West DW, Whittemore AS.Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):359-63.
16492929
Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S.X chromosomal abnormalities in basal-like human breast cancer.Cancer Cell. 2006 Feb;9(2):121-32.
16473279
Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench
16434590
Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL.BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.Breast Cancer Res Treat. 2005 May;91(2):179-86.
15868446
Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR.Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins.Mol Cell Biol. 2000 May;20(10):3626-32.
10779352
Miron A, Schildkraut JM, Rimer BK, Winer EP, Sugg Skinner C, Futreal PA, Culler D, Calingaert B, Clark S, Kelly Marcom P, Iglehart JD.Testing for hereditary breast and ovarian cancer in the southeastern United States.Ann Surg. 2000 May;231(5):624-34.
10767783
Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, Deffenbaugh AM, Miron A, Marks JR, Futreal PA, Frank TS.Frequency of germline and somatic BRCA1 mutations in ovarian cancer.Clin Cancer Res. 1998 Oct;4(10):2433-7.
9796975
Glick JL, Meigs TE, Miron A, Casey PJ.RGSZ1, a Gz-selective regulator of G protein signaling whose action is sensitive to the phosphorylation state of Gzalpha.J Biol Chem. 1998 Oct 2;273(40):26008-13.
9748279
Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ.Overestimation of hereditary breast cancer risk.Ann Surg. 1998 Sep;228(3):375-84.
9742920
DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR.Distinct roles for E2F proteins in cell growth control and apoptosis.Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7245-50.
9207076
DeGregori J, Leone G, Ohtani K, Miron A, Nevins JR.E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity.Genes Dev. 1995 Dec 1;9(23):2873-87.
7498785
Miron A, Patel I, Bastia D.Multiple pathways of copy control of gamma replicon of R6K: mechanisms both dependent on and independent of cooperativity of interaction of tau protein with DNA affect the copy number.Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):
8022801
Natarajan S, Kaul S, Miron A, Bastia D.A 27 kd protein of E. coli promotes antitermination of replication in vitro at a sequence-specific replication terminus.Cell. 1993 Jan 15;72(1):113-20.
8380756
Miron A, Mukherjee S, Bastia D.Activation of distant replication origins in vivo by DNA looping as revealed by a novel mutant form of an initiator protein defective in cooperativity at a distance.EMBO J. 1992 Mar;11(3):1205-16.
1547780
MacAllister TW, Kelley WL, Miron A, Stenzel TT, Bastia D.Replication of plasmid R6K origin gamma in vitro. Dependence on dual initiator proteins and inhibition by transcription.J Biol Chem. 1991 Aug 25;266(24):16056-62.
1651932

Advanced search
DF/HCC Directory Login Update Member Profile Change Account Settings Applying for Membership Benefits Requirements Responsibilities	Steven J. Isakoff, M.D. Ph.D. Publications Isakoff SJ.PARP Inhibition Outside of BRCA Mutation Carriers.Clin Adv Hematol Oncol. 2010 Nov;8(11):757-8. 21326153 Isakoff SJ, Baselga J.Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2011 Feb 1;29(4):351-4. 21172881 Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.Rapid targeted mut 20432502 Isakoff SJ.Triple-negative breast cancer: role of specific chemotherapy agents.Cancer J.;16(1):53-61. Review. 20164691 Mina L,Krop I,Zon RT,Isakoff SJ,Schneider CJ,Yu M,Johnson C,Vaughn LG,Wang Y,Hristova-Kazmierski M,Shonukan OO,Sledge GW,Miller KD.A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and 19214387 Naffar-Abu-Amara S, Shay T, Galun M, Cohen N, Isakoff SJ, Kam Z, Geiger B.Identification of novel pro-migratory, cancer-associated genes using quantitative, microscopy-based screening.PLoS ONE. 2008;3(1):e1457. 18213366 Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, 17021353 Ganesan S, Richardson AL, Wang ZC, Iglehart JD, Miron A, Feunteun J, Silver D, Livingston DM.Abnormalities of the Inactive X Chromosome Are a Common Feature of BRCA1 Mutant and Sporadic Basal-like Breast Cancer.Cold Spring Harb Symp Quant Biol. 2005;70:93 16869742 Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS.The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.Am J Surg. 2006 Jul;192(1):58-62. 16769276 Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu JS, Wong WH.Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data.BMC Bioinformatics. 2006;7:197. 16606446 Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, Li FP, Miron A, West DW, Whittemore AS.Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):359-63. 16492929 Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S.X chromosomal abnormalities in basal-like human breast cancer.Cancer Cell. 2006 Feb;9(2):121-32. 16473279 Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench 16434590 Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL.BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.Breast Cancer Res Treat. 2005 May;91(2):179-86. 15868446 Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR.Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins.Mol Cell Biol. 2000 May;20(10):3626-32. 10779352 Miron A, Schildkraut JM, Rimer BK, Winer EP, Sugg Skinner C, Futreal PA, Culler D, Calingaert B, Clark S, Kelly Marcom P, Iglehart JD.Testing for hereditary breast and ovarian cancer in the southeastern United States.Ann Surg. 2000 May;231(5):624-34. 10767783 Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, Deffenbaugh AM, Miron A, Marks JR, Futreal PA, Frank TS.Frequency of germline and somatic BRCA1 mutations in ovarian cancer.Clin Cancer Res. 1998 Oct;4(10):2433-7. 9796975 Glick JL, Meigs TE, Miron A, Casey PJ.RGSZ1, a Gz-selective regulator of G protein signaling whose action is sensitive to the phosphorylation state of Gzalpha.J Biol Chem. 1998 Oct 2;273(40):26008-13. 9748279 Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ.Overestimation of hereditary breast cancer risk.Ann Surg. 1998 Sep;228(3):375-84. 9742920 DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR.Distinct roles for E2F proteins in cell growth control and apoptosis.Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7245-50. 9207076 DeGregori J, Leone G, Ohtani K, Miron A, Nevins JR.E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity.Genes Dev. 1995 Dec 1;9(23):2873-87. 7498785 Miron A, Patel I, Bastia D.Multiple pathways of copy control of gamma replicon of R6K: mechanisms both dependent on and independent of cooperativity of interaction of tau protein with DNA affect the copy number.Proc Natl Acad Sci U S A. 1994 Jul 5;91(14): 8022801 Natarajan S, Kaul S, Miron A, Bastia D.A 27 kd protein of E. coli promotes antitermination of replication in vitro at a sequence-specific replication terminus.Cell. 1993 Jan 15;72(1):113-20. 8380756 Miron A, Mukherjee S, Bastia D.Activation of distant replication origins in vivo by DNA looping as revealed by a novel mutant form of an initiator protein defective in cooperativity at a distance.EMBO J. 1992 Mar;11(3):1205-16. 1547780 MacAllister TW, Kelley WL, Miron A, Stenzel TT, Bastia D.Replication of plasmid R6K origin gamma in vitro. Dependence on dual initiator proteins and inhibition by transcription.J Biol Chem. 1991 Aug 25;266(24):16056-62. 1651932
Site Map Site Feedback Web Privacy Policy